Ownership and insider activity for None (GDTC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies.
Price
| Price | $0.89 |
| Market Cap | $10M |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $374424 | $887223 | $2.5M | $1.6M | $9.0M | $5.0M | $2.1M |
| Short-term Investments | $84798 | $43586 | $15267 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | $18777 | $103859 |
| Inventory | $48116 | $240971 | $432590 | $578854 | $680586 | $838640 | $1.1M |
| Total Current Assets | $549014 | $1.5M | $3.3M | $2.5M | $10.1M | $6.0M | $3.7M |
| Property, Plant & Equipment | $2.4M | $2.3M | $2.5M | $2.5M | $2.1M | $3.3M | $3.7M |
| Goodwill | $358 | $356 | $356 | $357 | $356 | $355 | $355 |
| Intangible Assets | $36000 | $44991 | $31740 | $18538 | $12090 | $92674 | $124539 |
| Total Assets | $2.9M | $3.8M | $6.1M | $5.3M | $12.4M | $10.1M | $8.0M |
| Accounts Payable | $12454 | $18956 | $46356 | $14695 | $24684 | $38623 | $124742 |
| Short-term Debt | $36127 | $2.4M | $2.7M | $3.8M | $34018 | $37641 | $40847 |
| Total Current Liabilities | $376648 | $2.7M | $2.9M | $4.2M | $718905 | $606487 | $709169 |
| Long-term Debt | $603395 | $591975 | $540379 | $471008 | $408887 | $394222 | $368656 |
| Total Liabilities | $1.0M | $3.3M | $3.5M | $4.7M | $1.1M | $1.0M | $1.1M |
| Retained Earnings | -$1.1M | -$3.0M | -$5.1M | -$8.2M | -$12.4M | -$14.8M | -$18.8M |
| Total Equity | $1.9M | $477015 | $2.6M | $589712 | $11.3M | $9.0M | $6.5M |
| Total Debt | $674609 | $3.0M | $3.3M | $4.2M | $449247 | $463147 | $482562 |
| Net Debt | $215387 | $2.1M | $732405 | $2.7M | -$8.6M | -$4.5M | -$1.6M |
| Working Capital | $172366 | -$1.3M | $346065 | -$1.7M | $9.4M | $5.4M | $3.0M |
Financial Health
| Piotroski F-Score | 2 |
| Altman Z-Score | 5.96 |
Related companies: CLGN · ENLV · LSTA · MTVA · NCNA · NRSN · NRXS
More sections of GDTC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks